Page last updated: 2024-11-13
sec-butyl-propylacetamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
sec-butyl-propylacetamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 44550483 |
CHEMBL ID | 1079991 |
SCHEMBL ID | 1577854 |
MeSH ID | M0571214 |
Synonyms (5)
Synonym |
---|
CHEMBL1079991 |
sec-butyl-propylacetamide |
SCHEMBL1577854 |
sec-butylpropylacetamide |
s-butyl-propylacetamide |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" This study describes synthesis and stereospecific comparative pharmacodynamics (PD, anticonvulsant activity and teratogenicity) and pharmacokinetic (PK) analysis of four individual SPD stereoisomers." | ( Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. Bialer, M; Finnell, RH; Hen, N; McDonough, JH; Shekh-Ahmad, T; Wlodarczyk, B; Yagen, B, 2013) | 0.39 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (66)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID765806 | Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 32 mA-current- for 3 secs induced seizures after 0.25 to 0.5 hrs by 6Hz psychomotor seizure test | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID684370 | Anticonvulsant activity in ip dosed Sprague-Dawley albino rat assessed as protection against pilocarpine-induced status epilepticus after 0.5 hrs | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. |
AID470094 | Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 4 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID765808 | Neurotoxicity in ip dosed albino CF1 mouse assessed as minimal motor impairment after 0.25 to 0.5 hrs | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765795 | Protection against kainic acid-induced spontaneous electrographic seizures in combined medial entorhinal cortex hippocampal brain slices of albino Sprague-Dawley rat assessed as burst duration at 100 uM after 1 week relative to control | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765798 | Neurotoxicity in po dosed albino Sprague-Dawley rat assessed as minimal motor impairment after 0.5 to 1 hr | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765810 | Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous metrazol-induced seizures after 0.25 to 0.5 hrs | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765800 | Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures after 0.5 to 1 hr | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765804 | Anticonvulsant activity in ip dosed albino Sprague-Dawley rat assessed as protection against subcutaneous metrazol-induced seizures after 0.25 to 0.5 hrs | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765809 | Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures after 0.25 to 0.5 hrs | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID1312142 | Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 6 Hz current-induced seizures by psychomotor test | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. |
AID470091 | Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 0.5 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID1312145 | Neurotoxicity in ip dosed albino CF1 mouse assessed as motor impairment by rotorod test | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. |
AID765790 | Teratogenicity in SWV/Fnn mouse assessed as live fetuses at 283 mg/kg, ip on day 8.5 of gestation (Rvb = 93.7 %) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765783 | Teratogenicity in SWV/Fnn mouse assessed as fetuses with neural tube defects at 141 mg/kg, ip on day 8.5 of gestation relative to vehicle-treated control | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID470095 | Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 4 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID765802 | Anticonvulsant activity in ip dosed albino Sprague-Dawley rat nerve agent seizure model assessed as termination of soman-induced electrographic and convulsive seizures administered 20 mins post seizure measured after 0.25 to 0.5 hrs | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765779 | Anticonvulsant activity in ip dosed guinea pig assessed as protection against soman-induced electrographic and convulsive seizures administered 40 mins post seizure | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765780 | Anticonvulsant activity in ip dosed rat assessed as protection against soman-induced electrographic and convulsive seizures administered 40 mins post seizure | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID1312144 | Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CF1 mouse to ED50 for anticonvulsant activity in ip dosed 6 Hz current-induced seizure albino CF1 mouse model | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. |
AID470102 | Antiallodynic activity in ip dosed rat assessed as protection against spinal nerve ligation-induced neuropathic pain | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID470100 | Neurotoxicity in CF1 mouse assessed as protection against motor impairment at 100 mg/kg, ip after 4 hrs by rotarod test | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID765777 | Solubility of the compound in water | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID1312143 | Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 6 Hz current-induced seizure by measuring time to peak effect | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. |
AID470088 | Antiepileptic activity in CF1 mouse assessed as inhibition of maximal electroshock-induced seizures at 100 mg/kg, ip after 4 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID470115 | Anticonvulsant activity in ip dosed albino Sprague-Dawley rat assessed as protection against pilocarpine-induced seizure | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID470111 | Anticonvulsant activity in albino Sprague-Dawley rat assessed as protection against pilocarpine-induced seizure at 130 mg/kg, ip treated after 30 mins of pilcarpine challenge | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID470099 | Neurotoxicity in CF1 mouse assessed as protection against motor impairment at 30 mg/kg, ip after 4 hrs by rotarod test | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID765788 | Teratogenicity in SWV/Fnn mouse assessed as normal fetuses at 283 mg/kg, ip on day 8.5 of gestation (Rvb = 100 %) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765813 | AUC in rat at 60 mg/kg, ip | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID1312140 | Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures by measuring time to peak effect | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. |
AID470103 | Antiepileptic activity in ip dosed CF1 mouse assessed as inhibition of maximal electroshock-induced seizures | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID470096 | Neurotoxicity in CF1 mouse assessed as protection against motor impairment at 30 mg/kg, ip after 0.5 hrs by rotarod test | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID765794 | Teratogenicity in SWV/Fnn mouse assessed as resorption at 283 mg/kg, ip on day 8.5 of gestation (Rvb = 6.3 %) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765801 | Neurotoxicity in ip dosed albino Sprague-Dawley rat assessed as minimal motor impairment after 0.25 to 0.5 hrs | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID470110 | Anticonvulsant activity in albino Sprague-Dawley rat assessed as protection against pilocarpine-induced seizure at 65 mg/kg, ip | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID1312150 | Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CF1 mouse to ED50 for protection against sound-induced seizures in ip dosed AGS-susceptible frings albino CF1 mouse | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. |
AID765817 | Terminal half life in rat at 60 mg/kg, ip | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765812 | Tmax in rat at 60 mg/kg, ip | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID1312139 | Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CF1 mouse to ED50 for anticonvulsant activity in ip dosed maximal subcutaneous metrazol-induced seizure albino CF1 mouse model | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. |
AID765807 | Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 44 mA-current- for 3 secs induced seizures after 0.25 to 0.5 hrs by 6Hz psychomotor seizure test | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765799 | Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against subcutaneous metrazol-induced seizures after 0.5 to 1 hr | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID470092 | Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 0.5 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID470087 | Antiepileptic activity in CF1 mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, ip after 4 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID470090 | Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, ip after 0.5 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID765784 | Teratogenicity in SWV/Fnn mouse assessed as fetuses with neural tube defects at 283 mg/kg, ip on day 8.5 of gestation relative to vehicle-treated control | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765796 | Protection against kainic acid-induced spontaneous electrographic seizures in combined medial entorhinal cortex hippocampal brain slices of albino Sprague-Dawley rat assessed as burst rate at 100 uM after 1 week relative to control | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765786 | Teratogenicity in SWV/Fnn mouse assessed as normal fetuses at 141 mg/kg, ip on day 8.5 of gestation (Rvb = 100 %) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765789 | Teratogenicity in SWV/Fnn mouse assessed as live fetuses at 141 mg/kg, ip on day 8.5 of gestation (Rvb = 93.7 %) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765815 | Apparent volume of distribution at steady state in rat at 60 mg/kg, ip | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID1312141 | Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous metrazol-induced seizures by measuring time to peak effect | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. |
AID470093 | Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, ip after 4 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID1312149 | Anticonvulsant activity in ip dosed AGS-susceptible frings albino CF1 mouse assessed as protection against sound-induced seizures | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. |
AID765814 | Cmax in rat at 60 mg/kg, ip | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765778 | Solubility of the compound in 5:1:4 solution of propylene glycol, alcohol and water | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765816 | Apparent clearance in rat at 60 mg/kg, ip | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID470084 | Antiepileptic activity in CF1 mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, ip after 0.5 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID470086 | Antiepileptic activity in CF1 mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID765792 | Teratogenicity in SWV/Fnn mouse assessed as resorption at 141 mg/kg, ip on day 8.5 of gestation (Rvb = 6.3 %) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID470101 | Neurotoxicity in CF1 mouse assessed as protection against motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID765805 | Anticonvulsant activity in ip dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures after 0.25 to 0.5 hrs | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID1312138 | Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous metrazol-induced seizures | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. |
AID470097 | Neurotoxicity in CF1 mouse assessed as protection against motor impairment at 100 mg/kg, ip after 0.5 hrs by rotarod test | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
AID765803 | Anticonvulsant activity in ip dosed albino Sprague-Dawley rat assessed as protection against pilocarpine-induced behavioral seizures administered 30 mins post seizure measured after 0.25 to 0.5 hrs | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID765811 | Mean residence time in rat at 60 mg/kg, ip | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. |
AID470089 | Antiepileptic activity in CF1 mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (7.14) | 29.6817 |
2010's | 13 (92.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.20) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (7.14%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (92.86%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |